Department of Endocrinology, Liuzhou People's Hospital, Liuzhou, China.
Eur Rev Med Pharmacol Sci. 2023 Jul;27(13):6170-6175. doi: 10.26355/eurrev_202307_32973.
The study aimed to evaluate the effects of effective antithyroid therapy on adiposity and skeletal muscle in patients with hyperthyroidism across gender and age groups.
A total of 57 adult hyperthyroid patients (21 males and 36 females) who underwent effective antithyroid medication from January 2018 to January 2021 at Liuzhou People's Hospital and the First Affiliated Hospital of Guangxi Medical University were recruited and followed up for one year to observe the long-term efficacy of the antithyroid therapy. The eligible patients were divided by age and gender groups into male group A (males of <40 years old, n=12), female group A (females of <40 years old, n=19), male group B (males of 40-59 years old, n=8), female group B (female of 40-59 years old, n=13), and group C (patients of ≥60 years old, including one male and four females). A cohort of 57 healthy individuals was also recruited as controls. A Dual Energy X-ray (DXA) was performed to measure changes in fat and lean tissue mass and grip strength of the dominant hand before and after treatment and the body fat percentage (BFP). The whole-body skeletal muscle mass index (ASMI) was calculated to evaluate the long-term effects of antithyroid therapy.
The eligible patients of all ages reported significantly increased total fat mass, body fat percentage, and body mass index (p<0.05). The total lean tissue mass was markedly increased in male and female group A (p<0.05), showed no significant changes in male and female group B (p>0.05), and exhibited a marked decline in group C (p<0.05). Significantly elevated ASMI after treatment was observed in male and female group A (p<0.05), while no significant changes were detected in ASMI after treatment in groups B and C (p>0.05). All patients in groups A and B exhibited enhanced grip strength, while the enhancement of grip strength in patients of group C was poor (p>0.05).
Effective anti-hyperthyroidism therapy improves fat mass and body fat percentage in patients of all ages. However, gender and age differences exist in the effectiveness of improvements in total muscle mass and ASMI. Suboptimal muscle mass recovery was reported in patients over 40 years after effective anti-hyperthyroid therapy.
本研究旨在评估有效抗甲状腺治疗对不同性别和年龄组甲亢患者肥胖和骨骼肌的影响。
2018 年 1 月至 2021 年 1 月,在柳州市人民医院和广西医科大学第一附属医院接受有效抗甲状腺药物治疗的 57 例成年甲亢患者(男 21 例,女 36 例)被招募并随访 1 年,以观察抗甲状腺治疗的长期疗效。符合条件的患者按年龄和性别分为 A 组男性(<40 岁,n=12)、A 组女性(<40 岁,n=19)、B 组男性(40-59 岁,n=8)、B 组女性(40-59 岁,n=13)和 C 组(≥60 岁患者,包括 1 名男性和 4 名女性)。还招募了 57 名健康个体作为对照组。治疗前后采用双能 X 线(DXA)测量脂肪和瘦组织质量和优势手握力的变化,计算体脂百分比(BFP)。计算全身骨骼肌质量指数(ASMI)以评估抗甲状腺治疗的长期效果。
所有年龄组的合格患者总脂肪质量、体脂百分比和体重指数显著增加(p<0.05)。A 组男性和女性的总瘦组织质量明显增加(p<0.05),B 组男性和女性的瘦组织质量无明显变化(p>0.05),C 组明显下降(p<0.05)。A 组男性和女性治疗后 ASMI 明显升高(p<0.05),B 组和 C 组治疗后 ASMI 无明显变化(p>0.05)。A 组和 B 组所有患者握力增强,C 组患者握力增强较差(p>0.05)。
有效抗甲状腺治疗可改善各年龄段患者的脂肪质量和体脂百分比。然而,在改善总肌肉质量和 ASMI 的效果方面存在性别和年龄差异。有效抗甲亢治疗 40 年后,患者的肌肉质量恢复不理想。